Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore ( jul , 10.1007/s41669-024-00507-5 , 2024)

被引：0
|
作者：
Ong, Clarence [1 ,2 ]
Briones, Jamaica [1 ,2 ]
Lim, Zhi Zhen [1 ,2 ]
Chandran, Nisha Suyien [3 ]
Lee, Haur Yueh [4 ]
Li, Benny Kaihui [5 ]
Yew, Yik Weng [5 ]
Wee, Hwee-Lin [1 ,2 ]
机构：
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2, Singapore 117549, Singapore
[2] Natl Univ Hlth Syst, 12 Sci Dr 2, Singapore 117549, Singapore
[3] Natl Univ Singapore Hosp, Singapore, Singapore
[4] Singapore Gen Hosp, Singapore, Singapore
[5] Natl Skin Ctr, Singapore, Singapore
来源：
PHARMACOECONOMICS-OPEN | 2024年 / 8卷 / 06期
关键词：
D O I：
10.1007/s41669-024-00516-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：961 / 961
页数：1
相关论文
共 9 条
  • [1] Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore
    Ong, Clarence
    Briones, Jamaica
    Lim, Zhi Zhen
    Chandran, Nisha Suyien
    Lee, Haur Yueh
    Li, Benny Kaihui
    Yew, Yik Weng
    Wee, Hwee-Lin
    PHARMACOECONOMICS-OPEN, 2024, 8 (06) : 809 - 822
  • [2] Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Narla, Shanthi
    Silverberg, Jonathan I.
    DERMATITIS, 2023, : 366 - 386
  • [3] Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Narla, Shanthi
    Silverberg, Jonathan I.
    DERMATITIS, 2024, 35 : S24 - S38
  • [4] COST-EFFECTIVENESS MODEL OF LEBRIKIZUMAB COMPARED TO DUPILUMAB IN THE TREATMENT OF AUSTRIAN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
    Schwarz, B.
    Sole-Feu, L.
    Akmaz, B.
    VALUE IN HEALTH, 2024, 27 (12)
  • [5] Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies
    Yew, Yik Weng
    Alagappan, Uma
    Aw, Derrick
    Chandran, Nisha Suyien
    Choo, Karen J. L.
    Chu, Roland
    Koh, Hong Yi
    Koh, Mark Jean Aan
    Lee, Shan Xian
    Neoh, Ching Yin
    Tan, Siyun Lucinda
    Tang, Mark
    Tay, Yong-Kwang
    Francis-Graham, Seth
    Lim, Andrew
    Lee, Haur Yueh
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2024, 53 (11) : 670 - 682
  • [6] Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China
    Shi, Yin
    Zhou, Yanwu
    Li, Shuishi
    Guan, Haijing
    Liu, Shao
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1180 - 1189
  • [7] Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore
    Yew, Yik Weng
    Yeo, Pei Ming
    JAAD INTERNATIONAL, 2023, 13 : 13 - 14
  • [8] Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China
    Chen, Yihui
    Cao, Qiaozhi
    Peng, Cong
    Zhou, Bingjing
    Jiang, Yu
    Chen, Xiang
    Li, Jie
    FRONTIERS OF MEDICINE, 2024, 18 (04) : 752 - 756
  • [9] The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan (Dec, 10.1007/s13300-024-01675-7, 2024)
    Aranishi, Toshihiko
    Igarashi, Ataru
    Hara, Kazuo
    Osumili, Beatrice
    Cai, Zhihong
    Mizogaki, Aska
    Sato, Manaka
    Takeuchi, Masakazu
    Minghetti, Alice
    Hunt, Barnaby
    Kadowaki, Takashi
    DIABETES THERAPY, 2025, 16 (03) : 447 - 447
1